Comprehensive Genomic Profiling for
Quicker, Smarter & Better test for treatment decision
What is TumorTrack Advance?
TumorTrack Advance is a next generation sequencing (NGS) assay consisting of DNA and RNA based testing which detects single nucleotide variants (SNVs), insertion-deletion mutations (InDels), copy number variants (CNVs), fusions, tumor mutation burden (TMB), microsatellite instability (MSI) and PD-L1 expression in multiple solid tumors.
Coverage of Biomarkers
Gastrointestinal Stromal Tumor
- According to ICMR report the number of Indians suffering from cancer is projected to increase to 29.8 million in 2025 from 26.7 million in 2021
- Males are at 9.81% risk to develop cancer before the age of 75 and females at 9.42%
- The most common types of cancer in males include lip, oral cavity, lung, stomach, colorectal, and esophagus, while in females it includes breast, lip, oral cavity, cervix, lung, and gastric cancers (in descending order)
Why you need the test?
Single holistic test for the diagnosis, prognosis and to determine treatment options (Targeted Therapy & Immunotherapy)
Actionable/Potentially actionable variants identified in cancer patient samples from published data:
|Test Details||Test Code||Sample Type||TAT|
|TumorTrack Advance (SNVs, InDels, CNVs, Fusions, TMB and MSI)||MGM1785 +PD-L1 Expression by IHC*||FFPE Tissue Block >10% Tumor content Histopathology Report||21 Working Days|
|TumorTrack Plus (SNVs, InDels, CNVs, Fusions, TMB and MSI)||MGM1785|
|TumorTrack Plus (SNVs, InDels, CNVs and Fusions)||MGM1879|
|TumorTrack + MSI||MGM1784|
|TumorTrack + TMB||MGM1556|
|TumorTrack without Fusions||MGM2559|
|Cancer type||Specimen||FFPE block requirement*||Tumor Purity Minimum||Limit of detection||Average depth of sequencing||Analytical sensitivity||Analytical specificity|
|All Solid Tumor Types||FFPE Tissue Block/Cytology Cell Block, Tissue in RNA later*||Cross-sectional tumor area of 25mm2 containing at least 40 μm of tumor tissue||>10% (as determined by Molecular Pathologist)||5% VAF for SV and InDels >10 Spanning Reads for Fusions >2.5-fold Change for CNV||>250X||99.15% (SNVs/InDels); 98% Fusions; ≥85-90% (CNVs)||99.9%|